Conséquences de la pandémie de COVID-19 sur le taux de péritonites de dialyse péritonéale : plaidoyer pour une formation continue ininterrompue

IF 0.7 4区 医学 Q4 UROLOGY & NEPHROLOGY
Lucas Jacobs , Philippe Clevenbergh , Frédéric Collart , Isabelle Brayer , Maria Mesquita , Maxime Taghavi , Christelle Fosso , Saleh Kaysi , Joëlle Nortier , Max Dratwa
{"title":"Conséquences de la pandémie de COVID-19 sur le taux de péritonites de dialyse péritonéale : plaidoyer pour une formation continue ininterrompue","authors":"Lucas Jacobs ,&nbsp;Philippe Clevenbergh ,&nbsp;Frédéric Collart ,&nbsp;Isabelle Brayer ,&nbsp;Maria Mesquita ,&nbsp;Maxime Taghavi ,&nbsp;Christelle Fosso ,&nbsp;Saleh Kaysi ,&nbsp;Joëlle Nortier ,&nbsp;Max Dratwa","doi":"10.1016/j.nephro.2022.07.401","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Peritonitis is a common complication of chronic peritoneal dialysis treatment contributing to both technique failure and/or death. Little is effectively known about the actual benefits of a continuous training program on peritonitis rates. In the present study, we measured the impact of our patients’ training protocol on peritonitis rates. We further studied which consequences the COVID-related disruption of our follow-up program had on peritonitis rates.</p></div><div><h3>Methods</h3><p>We present our yearly peritonitis rates since our patients’ training and retraining program was implemented in 2010. We then focused our study on three consecutive years: 2019, 2020 (emergence of COVID-19), and 2021, collecting microbiological data from each peritonitis episode. Statistical analysis were used to corroborate our findings.</p></div><div><h3>Results</h3><p>Since 2010, peritonitis rates declined linearly (R2<!--> <!-->=<!--> <!-->0,6556; df<!--> <!-->=<!--> <!-->8; <em>P</em> <!-->&lt;<!--> <!-->0.01) until its nadir in 2019 with 4 peritonitis episodes. The majority of infections were then treated in the outpatient Clinic. In 2020, our continuous technique evaluation decreased by 51% and 28 peritonitis episodes occurred, 47% secondary to strict cutaneous bacteria's, and 31% gastro-intestinal, irrespective of patients’ experience or peritoneal dialysis modality. The hospitalization rate reached 71%. Having restored our protocol, we decreased peritonitis rates by 50% in 2021.</p></div><div><h3>Conclusions</h3><p>Risk factors for peritonitis are identifiable and modifiable and require sustained intervention, continuous visual monitoring and training. These interventions significantly reduce peritonitis rates. Any brief interruption to patients’ technique evaluation may elevate peritonitis rates significantly.</p></div>","PeriodicalId":51140,"journal":{"name":"Nephrologie & Therapeutique","volume":"18 6","pages":"Pages 526-533"},"PeriodicalIF":0.7000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1769725522005557/pdfft?md5=ef10d9b261afd312773a51f72438f77b&pid=1-s2.0-S1769725522005557-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologie & Therapeutique","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1769725522005557","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Peritonitis is a common complication of chronic peritoneal dialysis treatment contributing to both technique failure and/or death. Little is effectively known about the actual benefits of a continuous training program on peritonitis rates. In the present study, we measured the impact of our patients’ training protocol on peritonitis rates. We further studied which consequences the COVID-related disruption of our follow-up program had on peritonitis rates.

Methods

We present our yearly peritonitis rates since our patients’ training and retraining program was implemented in 2010. We then focused our study on three consecutive years: 2019, 2020 (emergence of COVID-19), and 2021, collecting microbiological data from each peritonitis episode. Statistical analysis were used to corroborate our findings.

Results

Since 2010, peritonitis rates declined linearly (R2 = 0,6556; df = 8; P < 0.01) until its nadir in 2019 with 4 peritonitis episodes. The majority of infections were then treated in the outpatient Clinic. In 2020, our continuous technique evaluation decreased by 51% and 28 peritonitis episodes occurred, 47% secondary to strict cutaneous bacteria's, and 31% gastro-intestinal, irrespective of patients’ experience or peritoneal dialysis modality. The hospitalization rate reached 71%. Having restored our protocol, we decreased peritonitis rates by 50% in 2021.

Conclusions

Risk factors for peritonitis are identifiable and modifiable and require sustained intervention, continuous visual monitoring and training. These interventions significantly reduce peritonitis rates. Any brief interruption to patients’ technique evaluation may elevate peritonitis rates significantly.

2019冠状病毒病大流行对腹膜透析腹膜炎发生率的影响:倡导持续培训
背景:腹膜炎是慢性腹膜透析治疗的常见并发症,可导致技术失败和/或死亡。关于腹膜炎发病率持续培训计划的实际益处,我们所知甚少。在本研究中,我们测量了患者训练方案对腹膜炎发病率的影响。我们进一步研究了与covid相关的随访计划中断对腹膜炎发病率的影响。方法我们报告了自2010年实施患者培训和再培训计划以来的年度腹膜炎发生率。然后,我们将研究重点放在连续三年:2019年、2020年(COVID-19的出现)和2021年,收集每次腹膜炎发作的微生物学数据。统计分析被用来证实我们的发现。结果2010年以来,腹膜炎发生率呈线性下降(R2 = 0,6556;df = 8;P & lt;0.01),至2019年最低点,出现4次腹膜炎。大多数感染在门诊接受治疗。在2020年,我们的连续技术评估下降了51%,发生了28例腹膜炎,47%继发于严格的皮肤细菌,31%继发于胃肠道,与患者的经历或腹膜透析方式无关。住院率达71%。在恢复了我们的方案后,我们在2021年将腹膜炎的发病率降低了50%。结论腹膜炎的危险因素是可识别和可改变的,需要持续的干预、持续的目视监测和训练。这些干预措施显著降低了腹膜炎的发病率。患者技术评估的任何短暂中断都可能显著提高腹膜炎的发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nephrologie & Therapeutique
Nephrologie & Therapeutique 医学-泌尿学与肾脏学
CiteScore
0.80
自引率
14.30%
发文量
485
审稿时长
11.9 weeks
期刊介绍: Organe d''expression de la Société de Néphrologie, de la Société Francophone de Dialyse et de la Société de Néphrologie Pédiatrique, Néphrologie et Thérapeutique a pour vocation de publier des textes en français dans le domaine de la Néphrologie, qu''il s''agisse d''actualisation des connaissances, de recommandations de bonne pratique clinique, de publications originales, ou d''informations sur la vie des trois sociétés fondatrices. La variété des thèmes abordés reflète la richesse de la Néphrologie, qu''il s''agisse d''aspects fondamentaux issus de la physiologie, de l''immunologie, de l''anatomo-pathologie, ou de la génétique, ou de sujets de néphrologie clinique, notamment ceux en rapport avec les thérapeutiques néphrologiques, transplantation, hémodialyse et dialyse péritonéale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信